| Literature DB >> 36157163 |
Michael Gerard Baracy1, Karen Hagglund2, Sanjana Kulkarni3, Fareeza Afzal3, Katherine Arends4, Robert T Morris5, Leigh Ann Solomon3, Muhammad Faisal Aslam6, Logan Corey7.
Abstract
BACKGROUND: It has been theorized that 75%-80% of febrile neutropenia (FN) is caused by endogenous pathogens, while up to 20% of cases are thought to be caused by a viral infection. It is unknown if precautions such as masking and social distancing reduce the risk of FN in susceptible populations. AIM: To determine whether coronavirus disease 2019 (COVID-19) infection mitigation efforts, namely masking and social distancing, were associated with a reduction in the incidence of FN.Entities:
Keywords: COVID-19; Febrile neutropenia; Hematology; Malignancy; Public health; SARS-CoV-2
Year: 2022 PMID: 36157163 PMCID: PMC9346421 DOI: 10.5306/wjco.v13.i7.609
Source DB: PubMed Journal: World J Clin Oncol ISSN: 2218-4333
Baseline demographics
|
|
|
|
|
| Total ED visits | 5073081 (56.4) | 3906140 (43.6) | - |
| Visits with neutropenia | |||
| Male | 1572 (48) | 1189 (49) | 0.59 |
| Female | 1704 (52) | 1252 (51) | |
| Age (yr) | 55.1 ± 23.6 | 54.7 ± 23.7 | 0.55 |
| Visits with febrile neutropenia | |||
| Male | 2145 (48) | 616 (50) | 0.35 |
| Female | 2327 (52) | 629 (50) | |
| Age (yr) | 56.2 ± 22.6 | 50.3 ± 26.6 | < 0.0001 |
Data reported at mean ± SD or n (%) unless otherwise specified. ED: Emergency department.
Frequency of clinical relevant group diagnosis among patients with neutropenic and febrile neutropenia in Year 0 and Year 1
|
|
| |||||
|
|
|
|
|
|
|
|
| Diagnoses |
|
|
|
| ||
| Common infections | 1482 (45) | 974 (40) |
| 403 (55) | 255 (51) | 0.17 |
| Any malignancy | 1237 (38) | 833 (34) |
| 276 (37) | 182 (36) | 0.65 |
| Solid malignancies | 722 (22) | 511 (21) | 0.32 | 120 (16) | 101 (20) | 0.09 |
| Hematologic malignancies | 564 (17) | 357 (15) |
| 165 (22) | 85 (17) |
|
| Benign neoplasms | 147 (5) | 111 (5) | 0.91 | 43 (6) | 17 (3) |
|
| Non-malignant blood dyscrasias | 1580 (48) | 1213 (50) | 0.27 | 315 (43) | 227 (45) | 0.41 |
| Endocrine, nutritional, and metabolic disorders | 1485 (45) | 1119 (46) | 0.70 | 268 (36) | 200 (40) | 0.23 |
| Skin, musculoskeletal, psychiatric, and nervous system disorders | 1224 (37) | 870 (36) | 0.18 | 211 (29) | 134 (27) | 0.44 |
| Disorders of the cardiopulmonary system | 1639 (50) | 1125 (46) |
| 324 (44) | 210 (42) | 0.44 |
| Disorders of the gastrointestinal and genitourinary systems | 1332 (41) | 952 (39) | 0.21 | 226 (31) | 159 (32) | 0.72 |
| Coronavirus disease 2019 | 6 (0) | 207 (9) | < 0.0001 | 0 (0) | 45 (9) | - |
Includes the 13 mo prior to Michigan’s state-wide public health executive orders (PHEO) and coronavirus disease 2019 (COVID-19) mitigation efforts; March 1, 2019 to March 31, 2020.
Includes the 13 mo following Michigan’s state-wide PHEO and COVID-19 mitigation efforts; April 1, 2020 to April 31, 2021.
Data reported at n (%) unless otherwise specified.
Figure 1Incidence of febrile neutropenia in patients with an associated diagnosis of hematologic malignancy compared to those without a diagnosis of hematologic malignancy. Patients with a diagnosis of a hematologic malignancy were significantly more likely to be febrile than those without a diagnosis of hematologic malignancy in Year 0 (21.2% vs 29.3%, P < 0.0001). This difference was not seen after implementation of public health guidelines in Year 1 (20.2% vs 23.8%, P = 0.12).